Revolution Medicines' daraxonrasib doubles pancreatic cancer survival

A new drug called daraxonrasib, developed by Revolution Medicines, has shown a critical advance in treating metastatic pancreatic cancer. Results from a Phase 3 clinical trial, presented on May 31, 2026, demonstrated that daraxonrasib nearly doubled overall survival rates for patients with advanced pancreatic cancer, from 6.7 months to 13.2 months, and reduced the risk of death by 60% compared to standard chemotherapy. This drug targets the KRAS gene mutation, previously considered 'undruggable,' which drives over 90% of pancreatic tumors. Revolution Medicines will now seek formal approval from the United States — Food and Drug Administration and other global regulatory bodies, with potential for expedited review due to the significant survival benefit. This development is expected to shift the landscape of pancreatic cancer treatment towards more precise and personalized therapies.